赖诺普利
医学
糖尿病
心肌梗塞
血压
心脏病学
内科学
血管紧张素转换酶
药物治疗
肾脏疾病
重症监护医学
血管紧张素转换酶抑制剂
心力衰竭
疾病
内分泌学
作者
Anna Szyndler,Piotr Dobrowolski,Andrzej Januszewicz,Artur Mamcarz,Krzysztof Narkiewicz,Aleksander Prejbisz,Andrzej Tykarski,Jacek Wolf
出处
期刊:Choroby Serca i Naczyń
[VM Media Sp zo.o. - VMGroup SK]
日期:2023-08-01
卷期号:20 (1): 33-39
标识
DOI:10.5603/chsin.a2023.0002
摘要
Cardiovascular diseases share common factors and pharmacotherapy measures. The goal of cardiology is their effective treatment with drugs of proven efficacy and safety, in order to reduce the risk of cardiovascular morbidity and mortality. Lisinopril is one of the angiotensin-converting enzyme inhibitors, whose evidence of efficacy has been observed in a wide range of indications. Lisinopril has been studied in a wide spectrum of patient populations with arterial hypertension, high cardiovascular disease risk, obesity, elderly, in the acute phase of myocardial infarction, chronic heart failure, diabetes, diabetic kidney disease, and diabetic retinopathy. In all those studies, lisinopril was shown not only to help to lower blood pressure but also to positively affect target organ damage and present with a very good safety profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI